Vaccine · 2007
Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ceyhan Mehmet, Yildirim Inci, Balmer Paul, Riley Christine, Laher Gouri, Andrews Nick, Borrow Ray, Kurt Nese, Turgut Mehmet, Aydogan Aysel, Ecevit Cigdem, Uysal Gulnar, Schultze Viola
Аннотация
Like many other developing countries; there is no accurate information about the antibody levels against Neisseria meningitidis in Turkey. We collected serum samples from four health centers located in different geographic regions and stratified according to age in order to obtain a baseline seroprevalence of protective antibodies to meningococcal serogroup C and provide data on seroprevalence of IgG antibodies to serogroups A, C, W135 and Y. Sera were tested for serum bactericidal antibodies (SBA) to serogroup C meningococci using rabbit serum as the complement source and by a bead based assay for serogroup A, C, W135 and Y-specific IgG. It was observed that 30% and 12% of individuals within the study population had SBA titers of > or =8 and > or =128, respectively. Overall; at least 70% of the population are susceptible (SBA titer <8) to meningococcal serogroup C disease. The rate of susceptibility was highest in infants aged 7-12 months and young children (1-4 years). Regardless of age, for serogroup A, C, W135 and Y, 60.5%, 27.2%, 12.3% and 19.2% of subjects, respectively, had serogroup-specific IgG concentrations > or =2 microg/mL. These data highlight that a large proportion of the Turkish population are susceptible to serogroups C, W135 and Y and should be considered, along with serogroup-specific disease incidence data, in future decisions on possible meningococcal vaccination programmes.
Предметные рубрики MeSH
AdolescentAdultAge FactorsAgedAged, 80 and overAntibodies, BacterialChildChild, PreschoolFemaleHumansImmunoglobulin GInfantInfant, NewbornMaleMeningococcal InfectionsMicrobial ViabilityMiddle AgedNeisseria meningitidis, Serogroup ANeisseria meningitidis, Serogroup CNeisseria meningitidis, Serogroup W-135Neisseria meningitidis, Serogroup YSeroepidemiologic StudiesTurkey